{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T13:43:10Z","timestamp":1774359790902,"version":"3.50.1"},"reference-count":20,"publisher":"JLE","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T00:00:00Z","timestamp":1586476800000},"content-version":"am","delay-in-days":375,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.nephro.2019.02.008","type":"journal-article","created":{"date-parts":[[2019,4,10]],"date-time":"2019-04-10T07:17:30Z","timestamp":1554880650000},"page":"S7-S12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"S1","title":["Traitement des vascularites \u00e0 ANCA\u00a0: certitudes et controverses"],"prefix":"10.1684","volume":"15","author":[{"given":"Benjamin","family":"Terrier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18929","reference":[{"issue":"2","key":"10.1016\/j.nephro.2019.02.008_bib0110","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/art.1780370206","article-title":"Nomenclature of systemic vasculitides. Proposal of an international consensus conference","volume":"37","author":"Jennette","year":"1994","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.nephro.2019.02.008_bib0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012\u00a0revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.nephro.2019.02.008_bib0120","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/art.39450","article-title":"Long-term outcomes among participants in the WEGENT trial of remission-maintenance therapy for granulomatosis with polyangiitis (Wegener's) or microscopic polyangiitis","volume":"68","author":"Pu\u00e9chal","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.nephro.2019.02.008_bib0125","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/art.27763","article-title":"Improved outcome in 445\u00a0patients with Wegener's granulomatosis in a German vasculitis center over four decades","volume":"63","author":"Holle","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.nephro.2019.02.008_bib0130","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/MD.0b013e318205a4c6","article-title":"The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort","volume":"90","author":"Guillevin","year":"2011","journal-title":"Medicine"},{"issue":"1","key":"10.1016\/j.nephro.2019.02.008_bib0135","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1053\/ajkd.2003.50013","article-title":"Clinicopathologic predictors of death and ESRD in patients with pauci-immune necrotizing glomerulonephritis","volume":"41","author":"Kapitsinou","year":"2003","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1016\/j.nephro.2019.02.008_bib0140","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/ard.2010.137778","article-title":"Long-term patient survival in ANCA-associated vasculitis","volume":"70","author":"Flossmann","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.nephro.2019.02.008_bib0145","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/acr.20176","article-title":"Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis","volume":"62","author":"Walsh","year":"2010","journal-title":"Arthritis Care Res"},{"issue":"4","key":"10.1016\/j.nephro.2019.02.008_bib0150","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/art.39011","article-title":"Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy","volume":"67","author":"Pagnoux","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.nephro.2019.02.008_bib0155","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1213277","article-title":"Efficacy of remission-induction regimens for ANCA-associated vasculitis","volume":"369","author":"Specks","year":"2013","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.nephro.2019.02.008_bib0160","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.nephro.2019.02.008_bib0165","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1002\/art.24637","article-title":"A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis","volume":"60","author":"Jones","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.nephro.2019.02.008_bib0170","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.nephro.2019.02.008_bib0175","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.lpm.2013.08.003","article-title":"Rituximab: Recommendations of the French Vasculitis Study Group (FVSG) for induction and maintenance treatments of adult, antineutrophil cytoplasm antibody-associated necrotizing vasculitides","volume":"42","author":"Charles","year":"2013","journal-title":"Presse Med"},{"issue":"2","key":"10.1016\/j.nephro.2019.02.008_bib0180","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/art.1780350214","article-title":"Lack of superiority of steroids plus plasma exchange to steroids alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome. A prospective, randomized trial in 78\u00a0patients","volume":"35","author":"Guillevin","year":"1992","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.nephro.2019.02.008_bib0185","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2007010090","article-title":"Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis","volume":"18","author":"Jayne","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"19","key":"10.1016\/j.nephro.2019.02.008_bib0190","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.nephro.2019.02.008_bib0195","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/annrheumdis-2017-212768","article-title":"Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides","volume":"77","author":"Terrier","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.nephro.2019.02.008_bib0200","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/annrheumdis-2017-212878","article-title":"Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)","volume":"77","author":"Charles","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"26","key":"10.1016\/j.nephro.2019.02.008_bib0205","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1056\/NEJMoa0802311","article-title":"Azathioprine or methotrexate maintenance for ANCA-associated vasculitis","volume":"359","author":"Pagnoux","year":"2008","journal-title":"N Engl J Med"}],"container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725519300392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725519300392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.jle.com\/10.1016\/j.nephro.2019.02.008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T16:20:48Z","timestamp":1741191648000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1769725519300392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":20,"alternative-id":["S1769725519300392"],"URL":"https:\/\/doi.org\/10.1016\/j.nephro.2019.02.008","relation":{},"ISSN":["1769-7255"],"issn-type":[{"value":"1769-7255","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Traitement des vascularites \u00e0 ANCA\u00a0: certitudes et controverses","name":"articletitle","label":"Article Title"},{"value":"N\u00e9phrologie & Th\u00e9rapeutique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nephro.2019.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 francophone de n\u00e9phrologie, dialyse et transplantation.","name":"copyright","label":"Copyright"}]}}